Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Thrombosis
•
Hematology
•
Antiphospholipid Syndrome
•
Pregnancy
•
Hemostasis/Thrombosis
What guides your choice between prophylactic, intermediate, and full therapeutic dosing of enoxaparin in a woman with APLS and prior fetal loss with no hx of thromboembolic disease?
Related Questions
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
How often do you check weight and adjust anticoagulation dosing in pregnancy?
How long would you anticoagulate for a catheter associated DVT in pregnancy?
Does a positive lupus anticoagulant alone confer high enough risk that warfarin is preferred over DOACs in antiphospholipid syndrome?
For patients with a history of pregnancy loss, do you evaluate for PAI-1 polymorphisms as part of a thrombophilia workup?
How do you manage anticoagulation in a patient with DVT from likely malignant mechanical obstruction?
How would you manage symptomatic, bilateral subsegmental PE developed after long air travel?
What is your preferred management for renal artery thrombosis causing renal infarct of unclear etiology?
Would you recommend anticoagulation in subsequent pregnancies after symptomatic postpartum R ovarian vein thrombosis?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
